• About the Journal
    Exploration of Targeted Anti-tumor Therapy (eISSN 2692-3114), a peer-reviewed, open access online journal, publishes articles on all aspects of cancer research, including clinical diagnosis and analysis, case report, prevention, intervention treatment, pre-clinical and clinical trials of all types of cancers. Submissions with good originality, well-designed experiments and rigorous data are particularly welcomed.
    From the Editors-in-Chief
    It is a particularly exciting time to be involved in cancer research and I am delighted to take on the role of co-Editor-in-Chief of the new journal Exploration of Targeted Anti-tumor Therapy. The journal will provide a platform for publication of studies on all aspects of the development of targeted anti-cancer drugs and will appeal to a broad range of readers. I look forward to receiving submissions of your manuscripts describing cutting-edge research in this fast moving and important field.
    Graham Packham
    Co-Editor-in-Chief of Exploration of Targeted Anti-tumor Therapy
    I am really honored to take on the role of co-Editor-in-Chief of this new journal—Exploration of Targeted Anti-tumor Therapy. Like many colleagues, I spent a large part of my professional life researching new cancer therapies. The efforts of the scientific community have allowed the development of targeted therapies to affect significantly the course of the main tumors. In this scenario, ETAT wants to represent a platform for discussion and evaluation on all aspects related to the development of targeted therapies, from the identification of the target to its validation and clinical exploration, including the evaluation of biomarkers of activity and toxicity. We therefore await your contributions to build together a place of confrontation that favors scientific progress in the field of target therapies.
    Nicola Normanno
    Co-Editor-in-Chief of Exploration of Targeted Anti-tumor Therapy
    Latest Articles
    Open Access
    Review
    Possible applications of salvianolic acid B against different cancers
    Cancer is the second death causing disease worldwide after cardiovascular abnormalities. The difficulty in treating tumor cells with more precise targeted interventions and recurrence of cancer afte...
    Iram Shahzadi ... Reza Mohammadinejad
    Published: August 31, 2020 Explor Target Antitumor Ther. 2020;1:218-238
    DOI: https://doi.org/10.37349/etat.2020.00014
    This article belongs to the special issue Targeting Transcription Factors for Cancer Therapy
    View:119
    Download:5
    Times Cited: 0
    Open Access
    Review
    PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors
    BCL-XL is an anti-apoptotic protein that plays an important role in tumorigenesis, metastasis, and intrinsic or therapy-induced cancer drug resistance. More recently, BCL-XL has also been identified...
    Peiyi Zhang ... Guangrong Zheng
    Published: August 31, 2020 Explor Target Antitumor Ther. 2020;1:259-272
    DOI: https://doi.org/10.37349/etat.2020.00017
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:348
    Download:19
    Times Cited: 0
    Open Access
    Commentary
    Circulating cancer stem cells: an interesting niche to explore
    Federica Papaccio
    Published: August 31, 2020 Explor Target Antitumor Ther. 2020;1:253-258
    DOI: https://doi.org/10.37349/etat.2020.00016
    This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
    View:209
    Download:3
    Times Cited: 0
    Open Access
    Review
    Future directions and management of liquid biopsy in non-small cell lung cancer
    Lung cancer represents the world's most common cause of cancer death. In recent years, we moved from a generic therapeutic strategy to a personalized approach, based on the molecular char...
    Alessia Maria Cossu ... Marco Bocchetti
    Published: August 31, 2020 Explor Target Antitumor Ther. 2020;1:239-252
    DOI: https://doi.org/10.37349/etat.2020.00015
    This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
    View:299
    Download:5
    Times Cited: 0